Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.

The movement follows the announcement of a heads of agreement with Pro Medicus to establish a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million, with an additional A$10 million contingent upon U.S. Food and Drug Administration clearance of Echo IQ's EchoSolv heart-failure product. Analysts view this deal as a material endorsement from a global imaging technology leader, providing a timely boost to Echo IQ's cash position and significantly enhancing its immediate U.S. commercialization opportunity.

Analysts have responded positively to the news, with Petra Capital raising its price target on Echo IQ by 19% to A$1.30 per share and Ord Minnett increasing its target by 20% to A$1.80 per share. The FDA clearance is seen as a key catalyst, with parallels drawn to a previous successful investment by Pro Medicus in another ASX-listed company prior to its product receiving FDA approval.